Stephen Read

Swayampakula Ramakanth

Chad Yahn

Edward Woo

Scott Henry

- RenovoRx has initiated commercialization of its FDA-cleared **RenovoCath device**, generating over **$600,000 in revenue** in the first half of the year and targeting a **$400 million initial market opportunity**.  **[1574094_2145715_0]** **[1574094_2145715_3]** **[1574094_2145715_6]**  The company currently has **13 cancer centers** approved to purchase the device, with **four** actively treating patients, and expects to expand to **20 to 40+ customers** by the end of **2026**.  **[1574094_2145715_0]** **[1574094_2145715_8]** 
- The **TIGeR-PaC Phase III trial** for locally advanced pancreatic cancer is nearing enrollment completion, with final analysis anticipated in late **2026**.  **[1574094_2145715_0]** **[1574094_2145715_4]** **[1574094_2145715_5]**  Interim data from the trial demonstrated a **six-month survival benefit** (21.5 months vs. 15.5 months for the control arm) and a **65% reduction in adverse events**.  **[1574094_2145715_4]** 
- The company ended Q2 with **$12.3 million in cash**, providing a financial runway into late **2026**, with an annual burn of approximately **$850,000**.  **[1574094_2145715_6]**  RenovoRx is also in discussions with potential partners for commercial scaling or acquisition.  **[1574094_2145715_7]** **[1574094_2145715_8]**

RenovoRx (RNXT)